Karyopharm Therapeutics Inc. (KPTI) is a publicly traded Healthcare sector company. As of May 21, 2026, KPTI trades at $7.85 with a market cap of $161.81M and a P/E ratio of -0.48. KPTI moved +6.69% today. Year to date, KPTI is +7.84%; over the trailing twelve months it is +54.80%. Its 52-week range spans $3.51 to $16.95. Analyst consensus is strong buy with an average price target of $15.83. Rallies surfaces KPTI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
KPTI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. KPTI recently traded at $7.85. Market cap is $161.81M. P/E ratio is -0.48. Revenue is $151.12M.
| Metric | Value |
|---|---|
| Price | $7.85 |
| Market Cap | $161.81M |
| P/E Ratio | -0.48 |
| EPS | $-16.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.95 |
| 52-Week Low | $3.51 |
| Volume | 223 |
| Avg Volume | 0 |
| Revenue (TTM) | $151.12M |
| Net Income | $-194.97M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $146.07M | $-196.04M | $-17.93 |
| 2023 | $146.03M | $-143.10M | $-1.25 |
| 2022 | $157.07M | $-165.29M | $-2.02 |
| 2021 | $209.82M | $-124.09M | $0.00 |
7 analysts cover KPTI: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.83.